New Insights into Limbic-Predominant Age-Related TDP-43 Encephalopathy (LATE) and Alzheimer Disease

Researchers have unveiled significant findings in the characterization of limbic-predominant age-related transactive response DNA-binding protein 43 kDa encephalopathy (LATE) and its coexistence with Alzheimer's disease (AD) using [18F]FDG PET and MRI imaging. The study provides a deeper understanding of these neurodegenerative conditions, especially given LATE's clinical similarities to AD in aging populations.

In this study, published in "The Journal of Nuclear Medicine," a comprehensive analysis was conducted on 944 [18F]FDG PET cases from cognitive disorder clinics. Researchers aimed to identify in vivo biomarkers that could effectively distinguish LATE from AD or confirm their co-pathologies. The research team developed 3D stereotactic surface projection PET templates based on autopsy-confirmed cases from the Alzheimer's Disease Neuroimaging Initiative and data from the University of Utah. These templates helped in differentiating LATE from AD by comparing z-score maps created from normal PET scans of a control group.

The findings revealed that among the examined cases, 13% were categorized as probable LATE, with 2.4% classified as pure LATE and 10.6% as having both LATE and AD (LATE+AD). Moreover, 23.7% were identified as probable AD without the presence of LATE. A critical insight from MRI volumetry was the pronounced atrophy of the medial temporal lobe in pure LATE cases, with a statistically significant difference (P < 0.001). In contrast, mixed LATE+AD cases showed notable vulnerabilities in both the orbitofrontal gyrus and lateral temporal lobe, also significant at P = 0.001 and P < 0.001, respectively.

Subsequent analysis further identified the entorhinal cortex and amygdala as distinctive regions for differentiating mixed LATE+AD cases from pure LATE and pure AD, with significant findings for each comparison (P = 0.05 and P < 0.001). The assessment also revealed that LATE+AD copathologies demonstrated synergistic effects, leading to prominent lateralized metabolic brain changes, predominantly on the left side. This lateralization was observed in both PET and MRI analyses, reinforcing the additive impact of having both pathologies.

The study's conclusion emphasizes the importance of recognizing LATE, particularly when it coexists with AD, as it presents unique challenges in diagnosis and treatment. The identified regional brain atrophy patterns in LATE and LATE+AD cases further contribute to targeted diagnostic approaches, offering potential pathways for future research and therapeutic development. The authors advocate for continued exploration into the synergistic interaction between LATE and AD to improve clinical outcomes and refine neuroimaging diagnostic techniques.

The study, led by Pei Ing Ngam, Yoshimi Anzai, and their colleagues, marks a significant step forward in understanding the complexities of neurodegenerative diseases affecting older adults. The detailed analysis of imaging biomarkers and their implications for clinical practice holds promise for enhanced patient care and tailored treatment strategies.